Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a study titled ‘A Phase 2b/3, Randomized, ...

New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.

Merck completes $10B acquisition of Verona Pharma, adding Ohtuvayre — the first new inhaled COPD therapy in over 20 years.

PHILADELPHIA (WPVI) -- COPD is one of the nation's biggest health problems - up to 24 million Americans may suffer from it. Temple Health is involved in trials for an innovative treatment to cut COPD ...

Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...

Using a care pathway focused on chronic obstructive pulmonary disease (COPD) can lead to shorter hospital stays, increased referrals to pulmonary rehabilitation, and improved standardization of care, ...

In one of the biggest health care deals of 2025, the pharmaceutical giant Merck has acquired the British drugmaker Verona Pharma for roughly $10 billion. Merck announced its purchase of the publicly ...

When breathing becomes a daily battle, even the simplest acts can feel exhausting. Now, a new study has found the key to ...

Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation ...

Recent research suggests that certain biologic medications called monoclonal antibodies may help treat emphysema more effectively than some current therapies. These medications include benralizumab ...